Ethris, industry partner of CNATM and based in Planegg, has secured EUR 30 million in financing from the European Investment Bank (EIB) under HERA Invest. The funding will support the further clinical development of Ethris’s mRNA-based product pipeline, including the antiviral candidate ETH47 for virus-driven exacerbations of asthma and COPD, as well as other programmes for respiratory diseases and pandemic preparedness.

Official press release